Read Our Latest Stories

Many life science marketers know exactly who they want to reach, but struggle to target researchers based on what they are exploring, which can signal near-term scientific interest and what they may be actively working on. Traditional audience targeting often relies on job titles, institutions, or broad scientific categories. The problem is that these signals rarely capture the specific scientific context driving interest at a given moment.

Many life science marketing teams discover the same problem when they try to scale scientific journal advertising. What works well with one publisher often becomes difficult to manage across several. A campaign that starts with one trusted journal partner can quickly expand into multiple insertion orders, reporting formats, approval processes, creative specifications, and timelines. Reach increases, but so does complexity. The result is often fragmentation, a situation where operational workload grows faster than campaign effectiveness.

Many life science marketers are noticing that generating qualified traffic is becoming harder and less predictable. Organic search is changing. AI-generated answers are becoming more prominent. Paid search costs continue to rise in competitive scientific categories. The challenge isn't that SEO and paid search no longer work but that relying on them alone has become increasingly risky.

One of the hardest challenges for life science companies is building awareness before researchers actively start looking for a solution. Search and performance marketing are highly effective at capturing existing demand. But they do much less to create awareness before a researcher enters a buying process. That raises an important question: How do successful life science brands stay visible before the search begins?

With ASH 2025 approaching (Dec 6–9), many in the hematology community are preparing for a surge of new data and announcements, a perfect moment to highlight emerging NIH funding patterns in the space.

This Lung Cancer Awareness Month, the stats are stark: lung cancer remains the deadliest cancer globally, with approximately 1.8 million deaths and 2.5 million new cases in 2022. For pharma and agency teams working in oncology, diagnostics or awareness campaigns, that’s not just a headline, it’s a call to action.

October’s Breast Cancer Awareness Month shines a light on both the immense global effort to defeat cancer and the critical role of communication in accelerating progress.

Raise awareness for Rare Diseases through contextual advertising in scientific & medical journals

MDPI leverages the PubGrade platform to enhance the advantages for both its advertising clients and internal marketing efforts. 

Caroline Cousquer from Takara Bio Europe reflects on eight years of collaboration with us.

The partnership opens new opportunities in contextual advertising across the Sage journals